Vanderbilt University School of Medicine, Nashville, Tennessee.
Department of Psychiatry and Behavioral Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee.
JAMA Netw Open. 2024 Feb 5;7(2):e2356430. doi: 10.1001/jamanetworkopen.2023.56430.
Co-located bridge clinics aim to facilitate a timely transition to outpatient care for inpatients with opioid use disorder (OUD); however, their effect on hospital length of stay (LOS) and postdischarge outcomes remains unclear.
To evaluate the effect of a co-located bridge clinic on hospital LOS among inpatients with OUD.
DESIGN, SETTING, AND PARTICIPANTS: This parallel-group randomized clinical trial recruited 335 adult inpatients with OUD seen by an addiction consultation service and without an existing outpatient clinician to provide medication for OUD (MOUD) between November 25, 2019, and September 28, 2021, at a tertiary care hospital affiliated with a large academic medical center and its bridge clinic.
The bridge clinic included enhanced case management before and after hospital discharge, MOUD prescription, and referral to a co-located bridge clinic. Usual care included MOUD prescription and referrals to community health care professionals who provided MOUD.
The primary outcome was the index admission LOS. Secondary outcomes, assessed at 16 weeks, were linkage to health care professionals who provided MOUD, MOUD refills, same-center emergency department (ED) and hospital use, recurrent opioid use, quality of life (measured by the Schwartz Outcome Scale-10), overdose, mortality, and cost. Analysis was performed on an intent-to-treat basis.
Of 335 participants recruited (167 randomized to the bridge clinic and 168 to usual care), the median age was 38.0 years (IQR, 31.9-45.7 years), and 194 (57.9%) were male. The median LOS did not differ between arms (adjusted odds ratio [AOR], 0.94 [95% CI, 0.65-1.37]; P = .74). At the 16-week follow-up, participants referred to the bridge clinic had fewer hospital-free days (AOR, 0.54 [95% CI, 0.32-0.92]), more readmissions (AOR, 2.17 [95% CI, 1.25-3.76]), and higher care costs (AOR, 2.25 [95% CI, 1.51-3.35]), with no differences in ED visits (AOR, 1.15 [95% CI, 0.68-1.94]) or deaths (AOR, 0.48 [95% CI, 0.08-2.72]) compared with those receiving usual care. Follow-up calls were completed for 88 participants (26.3%). Participants referred to the bridge clinic were more likely to receive linkage to health care professionals who provided MOUD (AOR, 2.37 [95% CI, 1.32-4.26]) and have more MOUD refills (AOR, 6.17 [95% CI, 3.69-10.30]) and less likely to experience an overdose (AOR, 0.11 [95% CI, 0.03-0.41]).
This randomized clinical trial found that among inpatients with OUD, bridge clinic referrals did not improve hospital LOS. Referrals may improve outpatient metrics but with higher resource use and expenditure. Bending the cost curve may require broader community and regional partnerships.
ClinicalTrials.gov Identifier: NCT04084392.
共置桥接诊所旨在促进患有阿片类药物使用障碍(OUD)的住院患者及时过渡到门诊治疗;然而,它们对住院时间(LOS)和出院后结果的影响仍不清楚。
评估共置桥接诊所对 OUD 住院患者 LOS 的影响。
设计、地点和参与者:这项平行组随机临床试验招募了 335 名在 2019 年 11 月 25 日至 2021 年 9 月 28 日期间在一家大型学术医疗中心及其桥接诊所附属的三级保健医院就诊的患有 OUD 的成年住院患者,这些患者由成瘾咨询服务接诊,并且没有现有的门诊临床医生为他们开具治疗 OUD 的药物(MOUD)。
桥接诊所包括在出院前后加强病例管理、开具 MOUD 处方,并转诊到共置桥接诊所。常规护理包括开具 MOUD 处方并转诊给提供 MOUD 的社区卫生保健专业人员。
主要结果是指数入院 LOS。次要结果在 16 周时评估,包括与提供 MOUD 的卫生保健专业人员建立联系、MOUD 续方、同一中心急诊部(ED)和医院使用、复发性阿片类药物使用、生活质量(用 Schwartz 结局量表-10 衡量)、过量、死亡率和成本。分析基于意向治疗进行。
在招募的 335 名参与者中(167 名随机分配到桥接诊所,168 名分配到常规护理),中位年龄为 38.0 岁(IQR,31.9-45.7 岁),194 名(57.9%)为男性。手臂之间的 LOS 没有差异(调整后的优势比 [AOR],0.94 [95%CI,0.65-1.37];P = .74)。在 16 周的随访中,转诊到桥接诊所的参与者的无住院天数较少(AOR,0.54 [95%CI,0.32-0.92]),再入院率较高(AOR,2.17 [95%CI,1.25-3.76]),且护理费用较高(AOR,2.25 [95%CI,1.51-3.35]),但急诊就诊(AOR,1.15 [95%CI,0.68-1.94])或死亡(AOR,0.48 [95%CI,0.08-2.72])没有差异与接受常规护理的患者相比。完成了 88 名参与者(26.3%)的随访电话。与接受常规护理的患者相比,转诊到桥接诊所的患者更有可能与提供 MOUD 的卫生保健专业人员建立联系(AOR,2.37 [95%CI,1.32-4.26]),并接受更多的 MOUD 续方(AOR,6.17 [95%CI,3.69-10.30]),并且不太可能经历过量(AOR,0.11 [95%CI,0.03-0.41])。
这项随机临床试验发现,在患有 OUD 的住院患者中,桥接诊所转诊并没有改善住院 LOS。转诊可能会改善门诊指标,但会增加资源使用和支出。要降低成本曲线,可能需要更广泛的社区和区域合作。
ClinicalTrials.gov 标识符:NCT04084392。